Search results with tag "Qt prolongation"
DRUG INDUCED QT PROLONGATION - GGC Medicines
ggcmedicines.org.ukof drug induced QT prolongation and drug interactions. Interactions There are three mechanisms by which drugs can interact and increase the risk of QT prolongation:6 Pharmacodynamic Interaction: The concurrent use of more than one drug that prolongs the QT interval increases the risk of torsades de pointes and ventricular arrhythmia.
DRUG NAME: Lenvatinib - BC Cancer
www.bccancer.bc.cabaseline and as needed during treatment in patients at risk for QT prolongation (e.g., congenital long QT syndrome, history of cardiac disease, or receiving concurrent therapy with QT/QTc interval-prolonging drugs ). Patients should report any …
Drugs Associated with QT Interval Prolongation
www.cpsbc.caDescribes whether the FDA-approved product labelling includes mention of QT prolongation, torsades de pointes, or both. 2–65. d . Drug reported in the product labelling to prolong the QT interval, but evidence to support such an effect is lacking or published data suggest otherwise. 1.
DRUG NAME: Oxaliplatin - BC Cancer
www.bccancer.bc.ca• QT prolongation and torsades de pointes are reported; use caution in patients with history of QT prolongation or cardiac disease and those receiving concurrent therapy with other QT prolonging
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.pharma.us.novartis.comFULL PRESCRIBING INFORMATION WARNING: QT PROLONGATION AND SUDDEN DEATHS Tasigna prolongs the QT interval. Prior to Tasigna administration and periodically, monitor for hypokalemia or hypomagnesemia and correct deficiencies (5.2).
HIGHLIGHTS OF PRESCRIBING INFORMATION (5.1,5.2,12.3)
www.accessdata.fda.govAvoid usc in patients with known QT prolongation, those with hypokalemia or hypomagnesemia, and those taking other drugs that prolong the QT interval (5.1, 12.5)
Drug Discovery and Preclinical Development
www.lehigh.eduCompound #1: hERG Test for QT Prolongation Values shown are Inhibition of Current (%) + SEM Test Compound % Inhibition SEM Compound 1 32.9 1.5 Positive Control 76.7 2.8 (tf diterfenadine 60 nM) Conducted by ChanTest, Inc; Covance GLP study 7252-117 Results: IC50 = 1.9 μM indicating low risk of cardiac arrhythmias based